l-nmma
Generic: tilarginine·Code: L-NMMA, tilarginine
l-nmma: sourced relationships with 1 company · 1 clinical trial tracked.
l-nmma evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect l-nmma to GRTX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could l-nmma → GRTX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
triple-negative breast cancer (TNBC)Metastatic Breast Cancer
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Galera Therapeutics, Inc. (GRTX) triple-negative breast cancer (TNBC) | Preclinical |
Clinical Trial Registry Records (1)
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)
Primary endpoint: Define recommended phase II dose (RP2D)
Interventionalopen36 targetStarted 2023-01Completion 2028-123 sites · United StatesThe Methodist Hospital Research Institute
Frequently asked questions
Which companies have sourced relationships with l-nmma?
l-nmma has dated SEC/FDA relationship records for Galera Therapeutics, Inc..
How many clinical trials involve l-nmma?
BioSniper tracks 1 clinical trial involving l-nmma.